+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 65 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and how the body processes a medication called NXT007 compared with another treatment called emicizumab for people aged 12 years and older who have severe or moderate congenital hemophilia A without inhibitors or any severity of hemophilia A with inhibitors. The study is a Phase III clinical trial focused on treatment to understand these two prophylaxis options better. Participants are randomly assigned to receive either NXT007 or emicizumab prophylaxis during the main treatment period. Emicizumab is given with a loading dose of 3 mgkg weekly for 4 weeks, followed by maintenance doses at different intervals, while NXT007 is administered subcutaneously as an integrated drug-device product. After the main treatment period, participants on NXT007 can continue this treatment, and those on emicizumab can switch to NXT007 during an open-label extension phase. During the study, participants will be monitored for bleeding rates, treatment burden, and safety through various assessments including questionnaires and blood tests. Researchers will track adverse events, immune responses to NXT007, and drug levels over approximately 3.5 years. The primary measure is the annualized rate of treated bleeds from month 2 onward, with study completion expected in 2032.

Age: 12Years +All GendersPhase 3
63 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
S

Actively Recruiting

Researchers are studying bleximenib, a drug being evaluated for treating acute leukemia in this Phase 12 clinical trial. The study aims first to find the recommended dose of bleximenib that is safe and tolerable in adults and children with relapsed or refractory acute leukemia. The later phase will assess how well bleximenib works at that dose to fight leukemia. Participants in the early part of the study will receive increasing oral doses of bleximenib to identify safe levels. Then, more participants will take the recommended dose to confirm safety and learn about the drugs effects. In the Phase 2 part, participants will continue to take bleximenib orally at the recommended dose to evaluate its ability to induce remission and assess safety. During the study, participants will be monitored for side effects and response to treatment for up to nearly five years. Researchers will measure safety by tracking adverse events and dose-limiting toxicities in Phase 1, and remission rates in Phase 2. Blood tests, plasma drug levels, and assessments of leukemia response will be performed regularly. The study will also evaluate overall survival, event-free survival, and transfusion independence as important outcomes.

Age: 2Years +All GendersPhase 1Phase 2
102 locations
R

Actively Recruiting

Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
186 locations
P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
O

Actively Recruiting

Researchers are evaluating denecimig Mim8 for adults diagnosed with acquired haemophilia A, a rare bleeding disorder. This Phase 3 open-label study aims to assess the safety and effectiveness of denecimig in reducing bleeding episodes in this population. The study is sponsored by Novo Nordisk AS and will follow participants for up to about one year and five months. Participants will receive subcutaneous injections of denecimig during the study. The treatment period includes a main part lasting 12 weeks followed by an extension phase up to 52 weeks. Denecimig plasma levels and the occurrence of antidrug antibodies will be monitored throughout the treatment. The study also tracks bleeding events and the use of other bleeding management therapies. During the study, participants will be closely monitored for treated and clinically relevant bleeding episodes, infections, and immune responses. The primary outcome is the number of treated bleeds during the first 12 weeks of treatment. Secondary outcomes include bleeding frequency, treatment days with bypassing agents or factor VIII products, and denecimig plasma concentration over one year. Participants are expected to follow study procedures and seek medical attention as needed during the approximately 73-week study period.

Age: 18Years +All GendersPhase 3
83 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of JNJ-79635322 compared to teclistamab in adults with relapsed or refractory multiple myeloma who have received 1 to 3 prior treatments, including an anti-CD38 antibody and lenalidomide. This phase 3 randomized study aims to assess how well these treatments work in controlling the disease and improving patient outcomes. Participants will receive subcutaneous injections of either JNJ-79635322 for a limited time or until intolerable side effects occur, or teclistamab as a subcutaneous injection until disease progression or intolerable toxicity. The study compares these two treatment approaches in parallel groups to observe differences in clinical response and safety. During the study, participants will be regularly monitored with laboratory tests and evaluations to measure responses such as complete response, progression-free survival, and quality of life. Researchers will track side effects, symptoms, and functioning over up to approximately 41 months. The study includes detailed assessments using questionnaires and laboratory parameters to understand treatment impact and safety throughout the participation period.

Age: 18Years +All GendersPhase 3
173 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations

1-10 of 65

1